|
SRRM1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.50089981846236E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.86080001091705E-09 |
| Normal-vs-Stage2 |
4.79170000011742E-07 |
| Normal-vs-Stage3 |
1.03719999255958E-09 |
| Normal-vs-Stage4 |
7.74929999947105E-07 |
| Stage1-vs-Stage2 |
1.908580E-01 |
| Stage1-vs-Stage3 |
8.447600E-02 |
| Stage1-vs-Stage4 |
5.380200E-01 |
| Stage2-vs-Stage3 |
9.671400E-01 |
| Stage2-vs-Stage4 |
5.656800E-01 |
| Stage3-vs-Stage4 |
5.182200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.98279981112171E-10 |
| Normal-vs-AfricanAmerican |
3.181400E-03 |
| Normal-vs-Asian |
2.620700E-04 |
| Caucasian-vs-AfricanAmerican |
3.684400E-01 |
| Caucasian-vs-Asian |
3.490800E-01 |
| AfricanAmerican-vs-Asian |
8.735800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.14669981580107E-10 |
| Normal-vs-Female |
8.40630010046084E-10 |
| Male-vs-Female |
4.929600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.11530000182591E-08 |
| Normal-vs-Age(41-60Yrs) |
3.51860000025184E-08 |
| Normal-vs-Age(61-80Yrs) |
1.82320047947826E-10 |
| Normal-vs-Age(81-100Yrs) |
6.150100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.996800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.068100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.325800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.913630E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.400600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.280400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.204400E-02 |
| Classical-VS-Follicular |
1.758460E-03 |
| Classical-VS-Other |
5.897600E-01 |
| Classical-VS-Normal |
4.57200000081315E-08 |
| Tall-VS-Follicular |
8.019600E-01 |
| Tall-VS-Other |
5.303600E-01 |
| Tall-VS-Normal |
4.96519999559908E-08 |
| Follicular-VS-Other |
5.702800E-01 |
| Follicular-VS-Normal |
2.37419994775223E-09 |
| Other-VS-Normal |
1.817760E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9786999816418E-09 |
| Normal-vs-N1 |
1.59771000000086E-05 |
| N0-vs-N1 |
5.643800E-01 |
|
|
